Related Experiment Video

Updated: Feb 9, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences

Francesca Mazzoni1, Paolo Petreni2, Marco Perna3

  • 11 Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Tumori
|June 14, 2018
PubMed

Insights

Afatinib effectively downstaged locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) in the neoadjuvant setting. Despite initial response, both patients relapsed, necessitating further afatinib treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Afatinib is a second-generation EGFR tyrosine kinase inhibitor used for EGFR-mutated non-small cell lung cancer (NSCLC).
  • Neoadjuvant therapy aims to reduce tumor burden before definitive treatment like surgery.

Observation:

  • Two cases of locally advanced, EGFR-mutated NSCLC received neoadjuvant afatinib for up to 3 months.
  • Both patients demonstrated significant tumor and lymph node reduction (downstaging) before surgery.

Findings:

  • Afatinib treatment led to downstaging in both NSCLC cases.
  • Disease relapse occurred at 9 and 10 months post-surgery in both patients, prompting re-initiation of afatinib therapy.

Implications:

  • Afatinib shows efficacy in neoadjuvant treatment of EGFR-mutated NSCLC, achieving tumor downstaging.
  • The study highlights the potential for disease relapse and the need for continued or re-initiated afatinib treatment in advanced NSCLC.
Keywords:
EGFRNon-small cell lung cancerafatinibneo-adjuvant

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.3K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.6K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
612
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
261
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
404
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
966